Plain-English translation of NCT06939595 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This Phase 3 trial is testing whether , a new immunotherapy medication, works as well as the well-known drug Keytruda when both are given alongside standard chemotherapy. The trial involves 225 people with advanced lung cancer that has not been treated before. Researchers want to compare how effective and safe the medication is compared to an already-approved treatment.
Immunotherapy has changed how doctors treat advanced lung cancer, but newer versions of these medications may offer benefits. This trial will help determine whether this medication is a good alternative option for patients who have not yet received cancer treatment.
Participants will be randomly assigned to receive either the new medication or the approved medication, both combined with standard chemotherapy (pemetrexed and a platinum drug). You would likely visit the clinic regularly for infusions, blood tests, and imaging scans to monitor how well the treatment is working. The trial is double-blind, meaning neither you nor your doctors will know which medication you're receiving, ensuring an unbiased comparison of safety and effectiveness.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
Georgia
Phase
Large-scale testing
Sponsor
Celltrion
Enrollment target
~225 participants
Started
January 2025
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.